Improving adjunctive pharmacotherapy for primary percutaneous coronary intervention in ST-segment elevation...

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Hematology

Background:

• Platelet abnormalities in acute coronary syndromes (ACS), especially STEMI, increase thrombotic risk.
• Preprocedural platelet reactivity and mean platelet volume correlate with ischemic events and poor reperfusion after primary PCI for STEMI.

Purpose of the Study:

• To evaluate the clinical implications of platelet abnormalities in STEMI patients undergoing primary PCI.
• To assess the safety and efficacy of bivalirudin monotherapy versus heparin plus GP IIb/IIIa blockade in the HORIZONS-AMI trial.
• To identify opportunities for improved antiplatelet strategies to mitigate stent thrombosis.

Main Methods:

• Analysis of platelet size and function in STEMI patients.
• Comparison of bivalirudin monotherapy with unfractionated heparin plus GP IIb/IIIa blockade in the HORIZONS-AMI trial.
• Assessment of ischemic and bleeding events, including acute stent thrombosis.

Main Results:

• Bivalirudin monotherapy showed a similar ischemic event rate but lower bleeding events (enhanced net clinical benefit) compared to heparin plus GP IIb/IIIa blockade.
• A significantly higher incidence of acute stent thrombosis was observed with bivalirudin monotherapy.
• Platelet reactivity and mean platelet volume are linked to adverse ischemic outcomes and impaired reperfusion.

Conclusions:

• While bivalirudin monotherapy offers a bleeding advantage in STEMI patients undergoing primary PCI, it increases the risk of acute stent thrombosis.
• Enhanced periprocedural platelet inhibition strategies are needed to reduce stent thrombosis.
• Optimizing adjunctive pharmacotherapy can potentially improve the overall safety and efficacy beyond bivalirudin monotherapy alone.